FDA Approves Durvalumab for Limited-Stage Small Cell Lung Cancer
Evidence for efficacy is based on the results from the ADRIATIC study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1576 results
EMA Recommends Granting a Conditional Marketing Authorisation for Belzutifan
It is intended for the treatment of patients with advanced clear cell renal cell carcinoma and von Hippel-Lindau disease-associated tumours
Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable to TACE
Findings from the EMERALD-1 and LEAP-012 studies
Omission of Surgical Axillary Staging Noninferior To Sentinel Lymph Node Biopsy in Patients with cN0, T1 or T2 Invasive Breast Cancer
Findings from the INSEMA study
Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed Childhood Standard-Risk B-Cell ALL of Average or High Risk of Relapse
Findings from the COG AALL1731 study
FDA Grants Accelerated Approval to Zenocutuzumab-zbco for Non-Small Cell Lung Cancer and Pancreatic Adenocarcinoma
Evidence for efficacy is based on the results from the eNRGy study
EMA Recommends Extension of Therapeutic Indications for Nivolumab and Ipilimumab
New indication concerns a combination of nivolumab and ipilimumab for first-line treatment of patients with dMMR/MSI-H unresectable or metastatic colorectal cancer
Active Monitoring Promising for Women with Low-Risk Ductal Carcinoma In Situ
Findings from the COMET study
Subcutaneous Daratumumab Monotherapy for Patients with High-Risk Smoldering Multiple Myeloma
Findings from the AQUILA study
EMA Recommends Extension of Indications for Osimertinib
New indication concerns treatment of adult patients with locally advanced, unresectable NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations
Imlunestrant Improves PFS Among Patients with ESR1-mutated ER-positive, HER2-negative ABC and In Combination with Abemaciclib Regardless of ESR1 Mutation Status
Findings from the EMBER-3 study
FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer
Evidence for efficacy is based on the results from the HERIZON-BTC-01 study